Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer

[1]  K. Hemminki,et al.  Single nucleotide polymorphisms (SNPs) are inherited from parents and they measure heritable events , 2005, Journal of carcinogenesis.

[2]  D. Goldstein,et al.  In genetic control of disease, does 'race' matter? , 2004, Nature Genetics.

[3]  K. Hemminki,et al.  Polymorphisms and haplotype structures in genes for transforming growth factor β1 and its receptors in familial and unselected breast cancers , 2004, International journal of cancer.

[4]  R. Shi,et al.  IGF‐I and breast cancer: A meta‐analysis , 2004, International journal of cancer.

[5]  X. Shu,et al.  Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[7]  S. Neuhausen,et al.  Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[9]  J. Struewing,et al.  Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes , 2004, BMC Cancer.

[10]  J. Witte,et al.  No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. , 2004, Cancer Epidemiology, Biomarkers and Prevention.

[11]  B. Leyland-Jones,et al.  Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. , 2003, Endocrine-related cancer.

[12]  K. Hemminki,et al.  Familial Breast Cancer: Scope for More Susceptibility Genes? , 2003, Breast Cancer Research and Treatment.

[13]  D. Easton,et al.  EMGM Abstracts , 2003, Genetic epidemiology.

[14]  D. Hunter,et al.  Polymorphic variation at the ‐202 locus in IGFBP3: Influence on serum levels of insulin‐like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk , 2003, International journal of cancer.

[15]  T. Habuchi,et al.  Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. , 2003, Cancer research.

[16]  J. Peto,et al.  The future of association studies of common cancers , 2003, Human Genetics.

[17]  S. Bustin,et al.  The GH–IGF-I axis and breast cancer , 2003, Trends in Endocrinology & Metabolism.

[18]  N. Probst-Hensch,et al.  IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort , 2003, British Journal of Cancer.

[19]  D. Hunter,et al.  Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  K. Hemminki,et al.  Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer. , 2002, Carcinogenesis.

[21]  F. Speizer,et al.  A sequence repeat in the insulin‐like growth factor‐1 gene and risk of breast cancer , 2002, International journal of cancer.

[22]  E. D. de Vries,et al.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility , 2002, Journal of medical genetics.

[23]  P. Vineis,et al.  Metabolic gene polymorphism frequencies in control populations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  R. Shi,et al.  Polymorphic CA repeats in the IGF-I gene and breast cancer , 2001, Breast Cancer Research and Treatment.

[25]  N E Day,et al.  Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.

[26]  M. Stampfer,et al.  Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  S. Narod,et al.  Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. , 2001, Molecular genetics and metabolism.

[28]  K. Hemminki,et al.  Risk factors and age‐incidence relationships for contralateral breast cancer , 2000, International journal of cancer.

[29]  V. Kataja,et al.  Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[31]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[32]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[33]  J. Bilezikian,et al.  Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. , 1998, The Journal of clinical endocrinology and metabolism.

[34]  D. Kleinberg.  Role of IGF-I in normal mammary development , 1998, Breast Cancer Research and Treatment.

[35]  P. Rotwein,et al.  17β-Estradiol Potently Suppresses cAMP-induced Insulin-like Growth Factor-I Gene Activation in Primary Rat Osteoblast Cultures* , 1997, The Journal of Biological Chemistry.

[36]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[37]  J. Kaprio,et al.  Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. , 1996, The Journal of clinical investigation.

[38]  A. Ward.  The insulin-like growth factor genes , 1992 .